Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2010

Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol. 2010;184(4):1328-33.

Lee SJ, Kim JY, Nogueiras R, Linares JF, Perez-Tilve D, Jung DY, et al. PKCzeta-regulated inflammation in the nonhematopoietic compartment is critical for obesity-induced glucose intolerance. Cell Metab. 2010;12(1):65-77.

Zippin JH, Chadwick PA, Levin LR, Buck J, Magro CM. Soluble adenylyl cyclase defines a nuclear cAMP microdomain in keratinocyte hyperproliferative skin diseases. J Invest Dermatol. 2010;130(5):1279-87.

Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010;3(117):ra29.

Rand JH, Wu X-, Quinn AS, Ashton AW, Chen PP, Hathcock JJ, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010;115(11):2292-9.

Liu L, Lee J, Zhou P. Navigating the nucleotide excision repair threshold. J Cell Physiol. 2010;224(3):585-9.

Rand JH, Wu X-, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010;19(4):460-9.

Westblade LF, Campbell EA, Pukhrambam C, Padovan JC, Nickels BE, Lamour V, et al. Structural basis for the bacterial transcription-repair coupling factor/RNA polymerase interaction. Nucleic Acids Res. 2010;38(22):8357-69.

Fong BA, Gillies AR, Ghazi I, LeRoy G, Lee KC, Westblade LF, et al. Purification of Escherichia coli RNA polymerase using a self-cleaving elastin-like polypeptide tag. Protein Sci. 2010;19(6):1243-52.

Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk. 2010;10(3):192-6.